The requesting Treating Physician submitted a request for access to drug (often referred to as Compassionate Use) to Novartis which was reviewed and approved by the medical team experienced with the drug and indication.~This program will provide access to patients until:~All participating countries have received marketing authorization and product is commercially available and accessible to all participating patient(s) or~Alternative treatment options are available and/or~In case of changes in the safety profile or a lack of overall efficacy of the product.
The purpose of this Treatment Plan is to allow access to trametinib and dabrafenib for eligible high-risk BRAF mutation-positive patients in the adjuvant treatment of melanoma after surgical resection. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.